by CN Bio. | Jul 27, 2021 | Press releases
Enables accurate modelling of the human colon and the mucosal barrier Provides new insights to the relationship between human microbiome and effect on human health Model to be integrated into CN Bio’s PhysioMimix™ OOC range of single- and multi-organ...
by CN Bio. | Jul 19, 2021 | Press releases
Lonza and CN Bio Announce Distribution Agreement Providing Prevalidated Hepatocytes for Use on Innovative Organ-on-a-chip Range Through a new distribution agreement, Lonza will supply a selection of cells to be prequalified for use in CN Bio’s innovative PhysioMimixTM...
by CN Bio. | Jul 15, 2021 | OOC Blog
The aim of organ-on-a-chip (OOC) technology is to more accurately replicate human physiology in vitro to overcome the relevance limitations of current approaches, and the field is progressing at a rapid pace! Many hundreds of academic researchers are choosing to work...
by CN Bio. | Jun 29, 2021 | Press releases
Next generation organ-on-a-chip (OOC) technology to be used to investigate the human gut microbiome for improving outcomes for patients with liver cirrhosis Adoption follows successful collaboration demonstrating value of PhysioMimix’s ability to recapitulate...
by CN Bio. | Jun 24, 2021 | Business
Today we signed a supply agreement with Dutch Company Cell4Pharma to access their industry-validated conditionally immortalised Renal Proximal Tubule Epithelial Cell (ciPTEC) lines for use with our PhysioMimix OOC Systems. Our PhysioMimix OOC systems, which are...
